AtriCure Inc. (ATRC)
AtriCure Inc. (ATRC) Stock Price, Analysis & Data
| Bid | 27.83 |
| Market Cap | 2.22B |
| Revenue (ttm) | 569.62M |
| Net Income (ttm) | 10.55M |
| Beta | 1.23 |
| EPS (ttm) | 0.21 |
| PE Ratio (ttm) | 207.43 |
| Forward PE | 100.89 |
| P/B (ttm) | 4.29 |
| P/S (ttm) | 3.89 |
| Earnings Date | May 5, 2026 |
| Ask | 49.7 |
| Volume | 461,157 |
| Avg. Volume (20D) | 918,691 |
| Open | 42.34 |
| Previous Close | 42.95 |
| Day's Range | 41.88 - 43.84 |
| 52-Week Range | 25.36 - 43.84 |
| Analyst | Buy |
| Price Target | 50 (14.78%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ATRC
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a ...
Financial Performance
In 2025, AtriCure's revenue was 534.53M, an increase of 14.88% compared to the previous year's 465.31M. Earnings were -11.45M, a decrease of -74.39%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for ATRC stock is "Buy". The 12-month stock price forecast is 50, which is upside of 14.78% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
